

Boadie W Dunlop

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4623150/publications.pdf](https://exaly.com/author-pdf/4623150/publications.pdf)

Version: 2025-02-01

166
papers

7,296
citations

54494

42
h-index

48559

82
g-index

190
all docs

190
docs citations

190
times ranked

10080
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of agreement between clinician-rated and patient-reported PTSD symptoms on intensive outpatient treatment outcomes. <i>Psychiatry Research</i> , 2025, 343, 116287.	3.4	0
2	Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges. <i>Brain Sciences</i> , 2025, 15, 161.	2.7	0
3	Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo. <i>Nature Mental Health</i> , 2024, 2, 164-176.	4.1	3
4	The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder. <i>Psychiatry Research</i> , 2024, 335, 115859.	3.4	1
5	The metabolome-wide signature of major depressive disorder. <i>Molecular Psychiatry</i> , 2024, 29, 3722-3733.	8.3	3
6	The capacity of brain circuits to enhance psychiatry. <i>Nature Medicine</i> , 2024, 30, 1834-1835.	25.6	0
7	A framework for assessment of adverse events occurring in psychedelic-assisted therapies. <i>Journal of Psychopharmacology</i> , 2024, 38, 690-700.	5.8	8
8	A preliminary descriptive report of the longevity of the effects of Swedish Massage therapy for subjects with Generalized Anxiety Disorder. <i>Journal of Bodywork and Movement Therapies</i> , 2023, 33, 176-181.	1.2	1
9	Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators. <i>Neuropsychopharmacology</i> , 2023, 48, 929-935.	5.4	13
10	Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence. <i>Neuropsychopharmacology</i> , 2023, 48, 1901-1909.	5.4	5
11	Circulating metabolites modulated by diet are associated with depression. <i>Molecular Psychiatry</i> , 2023, 28, 3874-3887.	8.3	12
12	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. <i>Psychiatry Research</i> , 2022, 308, 114354.	3.4	7
13	The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 84-92.	4.3	10
14	Metabolomic and inflammatory signatures of symptom dimensions in major depression. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 42-52.	4.3	45
15	A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. <i>Journal of Psychopharmacology</i> , 2022, 36, 368-377.	5.8	30
16	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression. <i>Journal of Affective Disorders</i> , 2022, 307, 254-263.	4.7	11
17	Rare copy number variation in posttraumatic stress disorder. <i>Molecular Psychiatry</i> , 2022, 27, 5062-5069.	8.3	2
18	Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102219.	2.7	45

#	ARTICLE	IF	CITATIONS
19	Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings. <i>Complementary Therapies in Medicine</i> , 2021, 56, 102593.	3.0	11
20	Navigating the Novel Psychotropics. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 1-2.	1.3	1
21	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 76-85.	1.3	1
22	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	11.3	50
23	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 172-179.	2.0	7
24	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. <i>Psychiatry Research</i> , 2021, 296, 113649.	3.4	12
25	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , 2021, 11, .	5.7	26
26	Dry Those Crying Eyes. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 295-303.	2.0	14
27	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. <i>Translational Psychiatry</i> , 2021, 11, .	5.7	58
28	Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. <i>CNS Spectrums</i> , 2021, 26, 169-170.	0.7	1
29	Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 501-503.	2.0	2
30	Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges. <i>Biological Psychiatry</i> , 2021, 90, 236-242.	1.7	19
31	Moving on With Monoamine Oxidase Inhibitors. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 50-52.	1.3	6
32	An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change.. <i>Psychological Services</i> , 2021, 18, 606-618.	1.7	32
33	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. <i>Scientific Reports</i> , 2021, 11, .	3.7	50
34	Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, .	2.7	12
35	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020, 57, .	2.8	20
36	Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms. <i>Journal of Psychiatric Research</i> , 2020, 120, 154-162.	3.1	11

#	ARTICLE	IF	CITATIONS
37	Somatic symptoms in treatment-naïve Hispanic and non-Hispanic patients with major depression. <i>Depression and Anxiety</i> , 2020, 37, 156-165.	3.9	26
38	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	4.7	41
39	A Virtual Standardized Patient-Based Assessment Tool to Evaluate Psychiatric Residents™ Psychopharmacology Proficiency. <i>Academic Psychiatry</i> , 2020, 44, 693-700.	0.8	16
40	ERICH3: vesicular association and antidepressant treatment response. <i>Molecular Psychiatry</i> , 2020, 26, 2415-2428.	8.3	18
41	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 933-945.	1.5	18
42	Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SORT) metric for a personalised psychiatry. <i>BMC Medicine</i> , 2020, 18, .	7.4	24
43	Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression. <i>Journal of Affective Disorders</i> , 2020, 266, 22-29.	4.7	24
44	150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression. <i>CNS Spectrums</i> , 2020, 25, 295-296.	0.7	0
45	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. <i>Psychiatry Research</i> , 2020, 290, 113017.	3.4	21
46	Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 111-112.	1.1	1
47	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 539-547.	0.5	5
48	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , 2019, 9, .	5.7	56
49	Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102147.	3.6	38
50	Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102149.	3.6	44
51	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, .	3.0	18
52	Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. <i>Journal of Psychiatric Research</i> , 2019, 114, 211-213.	3.1	1
53	The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. <i>World Psychiatry</i> , 2019, 18, 183-191.	12.0	75
54	Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. <i>Journal of Psychiatric Research</i> , 2019, 116, 178-184.	3.1	14

#	ARTICLE	IF	CITATIONS
55	49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial. <i>CNS Spectrums</i> , 2019, 24, 202-203.	0.7	1
56	Moving pharmacoepigenetics tools for depression toward clinical use. <i>Journal of Affective Disorders</i> , 2019, 249, 336-346.	4.7	26
57	Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. <i>American Journal of Psychiatry</i> , 2019, 176, 275-286.	10.5	47
58	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.9	53
59	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, .	3.4	22
60	Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. <i>Psychological Medicine</i> , 2019, 49, 1869-1878.	4.6	16
61	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. <i>Journal of Psychiatric Research</i> , 2019, 111, 59-67.	3.1	213
62	The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 361-379.	4.1	145
63	Model structure for protocol adherence utilizing a manualized therapeutic massage intervention. <i>Journal of Complementary and Integrative Medicine</i> , 2019, 16, .	1.4	4
64	When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates. <i>Journal of Anxiety Disorders</i> , 2019, 61, 89-97.	3.6	32
65	Pharmacogenetic Tests and Depressive Symptom Remission: A Meta-Analysis of Randomized Controlled Trials. <i>Pharmacogenomics</i> , 2019, 20, 37-47.	1.8	138
66	Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. <i>Journal of Affective Disorders</i> , 2018, 229, 111-119.	4.7	11
67	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 200-206.	2.0	15
68	Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. <i>Cancer</i> , 2018, 124, 546-554.	4.4	60
69	Test-Retest Reliability of the SERT Imaging Agent ¹¹ C-HOMADAM in Healthy Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 315-319.	6.6	1
70	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. <i>American Journal of Psychiatry</i> , 2018, 175, 251-261.	10.5	43
71	Imaging the Future of Major Depression. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 3s-3s.	1.3	0
72	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, .	4.3	35

#	ARTICLE	IF	CITATIONS
73	Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. <i>Depression and Anxiety</i> , 2018, 35, 992-1000.	3.9	29
74	Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. <i>Pharmacogenomics Journal</i> , 2018, 18, 613-622.	3.1	87
75	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al.. <i>American Journal of Psychiatry</i> , 2018, 175, 576-577.	10.5	2
76	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , 2018, 238, 1-7.	4.7	26
77	Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2018, 8, 37.	2.3	26
78	Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. <i>Neuron</i> , 2018, 99, 914-924.e3.	12.8	154
79	Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2018, 8, 64.	2.3	8
80	Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.. <i>Journal of Consulting and Clinical Psychology</i> , 2018, 86, 189-199.	4.2	14
81	The structure of personality disorders within a depressed sample: Implications for personalizing treatment. <i>Personalized Medicine in Psychiatry</i> , 2017, 1-2, 59-64.	0.4	3
82	D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 501.	14.1	236
83	549. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. <i>Biological Psychiatry</i> , 2017, 81, S222.	1.7	1
84	Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. <i>American Journal of Psychiatry</i> , 2017, 174, 546-556.	10.5	104
85	Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2017, 174, 533-545.	10.5	251
86	Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. <i>Depression and Anxiety</i> , 2017, 34, 246-256.	3.9	27
87	525. The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD. <i>Biological Psychiatry</i> , 2017, 81, S213.	1.7	0
88	688. The CRH-1 Receptor Antagonist Saga in Mood and Anxiety Disorders: The Good, the Bad and the Ugly. <i>Biological Psychiatry</i> , 2017, 81, S279.	1.7	1
89	597. Clinical Staging of Major Depression: Multimodal-Imaging Approach. <i>Biological Psychiatry</i> , 2017, 81, S241-S242.	1.7	0
90	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 82, 866-874.	1.7	77

#	ARTICLE	IF	CITATIONS
91	Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment. <i>Psychiatry Research</i> , 2017, 257, 386-392.	3.4	17
92	How Shall I Diagnose Thee? Let Me Count the Ways. <i>Biological Psychiatry</i> , 2017, 82, 306-308.	1.7	0
93	Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017, 7, 40.	2.3	42
94	Surveying Psychiatrists' Psychopharmacology Practices Across Common Clinical Scenarios. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 445-449.	1.3	1
95	Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). <i>Psychopharmacology</i> , 2017, 234, 2883-2895.	3.0	75
96	Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. <i>PLoS Biology</i> , 2017, 15, e2002690.	5.2	24
97	Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry?. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 3s-4s.	1.3	1
98	Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 156-173.	1.3	22
99	Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. <i>Psychoneuroendocrinology</i> , 2016, 69, 161-171.	2.5	32
100	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 481-490.	10.5	42
101	Assessing Residents' Confidence in the Context of Pharmacotherapy Competence. <i>Academic Psychiatry</i> , 2016, 41, 350-353.	0.8	9
102	When Should a Patient Be Declared Recovered From a Major Depressive Episode?. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1026-e1028.	2.9	5
103	Acute Swedish Massage Monotherapy Successfully Remediate Symptoms of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e883-e891.	2.9	30
104	Depression Worsening Associated With Lorcaserin. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 747-749.	2.0	4
105	Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 454-459.	2.0	9
106	Mediators of Sexual Functioning and Marital Quality in Chronically Depressed Adults with and Without a History of Childhood Sexual Abuse. <i>Journal of Sexual Medicine</i> , 2015, 12, 813-823.	0.4	30
107	Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 237-239.	2.5	38
108	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy. <i>JAMA Psychiatry</i> , 2015, 72, 1102.	14.1	145

#	ARTICLE	IF	CITATIONS
109	Prediction of treatment outcomes in major depressive disorder. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 669-672.	2.9	20
110	The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review. <i>Current Psychiatry Reviews</i> , 2015, 11, 222-234.	0.6	2
111	Antidepressant Signal Detection in the Clinical Trials Vortex. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e657-e659.	2.9	4
112	Use of Dialectical Behavior Therapy in Borderline Personality Disorder: A View From Residency. <i>Academic Psychiatry</i> , 2014, 31, 218-224.	0.8	6
113	A Randomized, Double-Blind Evaluation of α -Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans. <i>American Journal of Psychiatry</i> , 2014, 171, 640-648.	10.5	338
114	GENDER AS PREDICTOR AND MODERATOR OF OUTCOME IN COGNITIVE BEHAVIOR THERAPY AND PHARMACOTHERAPY FOR ADULT DEPRESSION: AN α -INDIVIDUAL PATIENT DATA α -META-ANALYSIS. <i>Depression and Anxiety</i> , 2014, 31, 941-951.	3.9	121
115	Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). <i>Behavioral Sciences (Basel, Switzerland)</i> , 2014, 4, 511-527.	2.3	42
116	How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. <i>Human Psychopharmacology</i> , 2014, 29, 528-536.	1.9	10
117	ENHANCING HISPANIC PARTICIPATION IN MENTAL HEALTH CLINICAL RESEARCH: DEVELOPMENT OF A SPANISH-SPEAKING DEPRESSION RESEARCH SITE. <i>Depression and Anxiety</i> , 2014, 31, 258-267.	3.9	25
118	Ziprasidone monotherapy is ineffective for bipolar-associated anxiety. <i>Evidence-Based Mental Health</i> , 2014, 17, 109-109.	8.0	0
119	Combination Psychotherapy and Antidepressant Medication Treatment for Depression: For Whom, When, and How. <i>Annual Review of Psychology</i> , 2014, 65, 267-300.	23.4	72
120	Corrigendum to α -Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder α -[<i>Psychiatr Res</i> 46 (2012) 375 α -381]. <i>Journal of Psychiatric Research</i> , 2014, 54, 141.	3.1	2
121	REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 379-390.	3.9	15
122	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	3.1	30
123	Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression. <i>Biological Psychiatry</i> , 2014, 76, 527-535.	1.7	114
124	MicroRNA 135 Is Essential for Chronic Stress Resiliency, Antidepressant Efficacy, and Intact Serotonergic Activity. <i>Neuron</i> , 2014, 83, 344-360.	12.8	310
125	Cognitive Effects of Quetiapine XR in Patients With Euthymic Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 383-385.	2.0	7
126	Neuroimaging-based biomarkers for treatment selection in major depressive disorder. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 479-490.	5.6	100

#	ARTICLE	IF	CITATIONS
127	Do alcohol use disorders destabilize the course of bipolar disorder?. Journal of Affective Disorders, 2013, 145, 1-10.	4.7	38
128	Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder. JAMA Psychiatry, 2013, 70, 821.	14.1	459
129	A Simple Question Answered: Adding Moderate-Dosage Lithium Does Not Help Patients With Bipolar Disorder. American Journal of Psychiatry, 2013, 170, 9-11.	10.5	1
130	Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder. PLoS ONE, 2013, 8, e78292.	2.5	29
131	Reconciling Variable Findings of White Matter Integrity in Major Depressive Disorder. Neuropsychopharmacology, 2013, 39, 1332-1339.	5.4	57
132	Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. Journal of Clinical Psychiatry, 2013, 74, 1010-1017.	2.9	76
133	US Psychiatric Residents's Treatment of Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2012, 32, 231-236.	2.0	12
134	A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites. Neuropsychopharmacology, 2012, 37, 2830-2836.	5.4	58
135	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. Journal of Psychiatric Research, 2012, 46, 1406-1413.	3.1	26
136	Pharmacology and neuroimaging of antidepressant action. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, , 643-655.	0.0	0
137	Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. Journal of Psychiatric Research, 2012, 46, 375-381.	3.1	62
138	Recovery and subsequent recurrence in patients with recurrent major depressive disorder. Journal of Psychiatric Research, 2012, 46, 708-715.	3.1	13
139	Preconsent education about research processes improved African Americans' willingness to participate in clinical research. Journal of Clinical Epidemiology, 2011, 64, 872-877.	4.0	21
140	The effects of sertraline on psychopathic traits. International Clinical Psychopharmacology, 2011, 26, 329-337.	1.7	18
141	Symptomatic and Functional Improvement in Employed Depressed Patients. Journal of Clinical Psychopharmacology, 2011, 31, 569-576.	2.0	69
142	Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD. CNS Spectrums, 2011, 16, 11-20.	0.7	17
143	Will current socioeconomic trends produce a depressing future for men?. British Journal of Psychiatry, 2011, 198, 167-168.	2.3	13
144	Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder. Journal of Psychiatric Research, 2011, 45, 24-28.	3.1	5

#	ARTICLE	IF	CITATIONS
145	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 96-103.	3.1	43
146	Public Health Consequences of State Immigration Laws. <i>Southern Medical Journal</i> , 2011, 104, 718-719.	0.5	8
147	Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 81-90.	2.9	42
148	An Additional Consideration for Comparisons of Antidepressants Versus Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 641-642.	2.0	1
149	Survey of Investigators' Opinions on the Acceptability of Interactions With Patients Participating in Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 323-327.	2.0	6
150	Should Sensitive Information From Clinical Trials Be Included in Electronic Medical Records?. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 685.	13.7	5
151	Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder. <i>Current Psychiatry Reviews</i> , 2010, 6, 28-45.	0.6	4
152	Test-retest reliability of the SERT imaging agent [11C]HOMADAM in healthy humans. <i>NeuroImage</i> , 2010, 52, S110.	4.8	0
153	Correlation between patient and clinician assessments of depression severity in the PREVENT study. <i>Psychiatry Research</i> , 2010, 177, 177-183.	3.4	41
154	Exploratory structural equation modeling of resting-state fMRI: Applicability of group models to individual subjects. <i>NeuroImage</i> , 2009, 45, 778-787.	4.8	57
155	Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i>International Clinical Psychopharmacology</i> , 2009, 24, 204-213.	1.7	25
156	Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. <i>International Clinical Psychopharmacology</i> , 2008, 23, 357-363.	1.7	14
157	Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008, 10, 222-228.	0.9	78
158	Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 614-619.	2.0	41
159	The Impact of HIPAA Authorization on Willingness to Participate in Clinical Research. <i>Annals of Epidemiology</i> , 2007, 17, 899-905.	1.7	26
160	The Role of Dopamine in the Pathophysiology of Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 327.	14.4	984
161	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. <i>Biological Psychiatry</i> , 2007, 62, 1371-1379.	1.7	38
162	Tiagabine for social anxiety disorder. <i>Human Psychopharmacology</i> , 2007, 22, 241-244.	1.9	29

#	ARTICLE	IF	CITATIONS
163	Psychosocial context of antidepressant response. <i>Biological Psychiatry</i> , 2005, 57, 314.	1.7	0
164	Commentary. primary care companion for CNS disorders, <i>The</i> , 2005, 7, .	0.7	0
165	Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996.. <i>Environmental Health Perspectives</i> , 2002, 110, 1047-1051.	8.6	27
166	Depression. , 0, , .		1